STRS Ohio’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

STRS Ohio’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-453	Closed	-$76K	–	2193
2020 Q2	$76K	Buy	+453	New	+$48.8K	﹤0.01%	1842

Other funds holding BCLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

STRS Ohio's BCLI Position: Q3 2020 in Review

STRS Ohio sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2020, closing a stake of 453 shares — an estimated $76K sold.

STRS Ohio first reported a position in BCLI in Q2 2020 and held it in 1 quarter. The position peaked at $76K in Q2 2020. 80 funds tracked by Wall St. Rank hold BCLI as of Q3 2020.

STRS Ohio reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2020 after selling out during the quarter.
STRS Ohio sold 453 BRAINSTORM CELL THERAPUTC shares in Q3 2020, an estimated $76K.
STRS Ohio first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 1 quarter.
STRS Ohio's BRAINSTORM CELL THERAPUTC position peaked at $76K in Q2 2020.
80 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2020.

Based on STRS Ohio's 13F filing for Q3 2020, filed 14 Dec 2020.